DrugPatentWatch Database Preview
OLUMIANT Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Olumiant patents expire, and when can generic versions of Olumiant launch?
Olumiant is a drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-four patent family members in forty-two countries.
The generic ingredient in OLUMIANT is baricitinib. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.
US ANDA Litigation and Generic Entry Outlook for Olumiant
Olumiant will be eligible for patent challenges on May 31, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 8, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for OLUMIANT
| International Patents: | 54 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 85 |
| Clinical Trials: | 2 |
| Patent Applications: | 42 |
| Drug Prices: | Drug price information for OLUMIANT |
| DailyMed Link: | OLUMIANT at DailyMed |
Generic Entry Opportunity Date for OLUMIANT
Generic Entry Date for OLUMIANT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for OLUMIANT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Thomas Benfield | Phase 3 |
| Washington University School of Medicine | Phase 1 |
Pharmacology for OLUMIANT
| Drug Class | Janus Kinase Inhibitor |
| Mechanism of Action | Janus Kinase Inhibitors |
Synonyms for OLUMIANT
| (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile |
| {1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile |
| 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile |
| 1187594-09-7 |
| 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile |
| 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile |
| 2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE |
| 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- |
| 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- |
| 3JW |
| AB0035958 |
| ABP001023 |
| AC-27404 |
| AJ-121247 |
| AK143352 |
| AKOS022186127 |
| AKOS025401933 |
| AM81232 |
| AMMD00005 |
| AOB87724 |
| AX8261519 |
| Baricitinib |
| Baricitinib (INCB28050 LY3009104) |
| Baricitinib (JAN/USAN/INN) |
| Baricitinib (LY3009104, INCB028050) |
| Baricitinib (LY3009104) |
| Baricitinib [USAN:INN] |
| baricitinib-ly3009104 |
| BC600315 |
| BCP04686 |
| BCP0726000031 |
| BCP9000380 |
| BDBM50021656 |
| C16H17N7O2S |
| CHEBI:95341 |
| CHEMBL2105759 |
| CS-0724 |
| D10308 |
| DB11817 |
| DS-7641 |
| DTXSID30152228 |
| EX-A413 |
| GTPL7792 |
| HMS3651L17 |
| HY-15315 |
| INCB 028050 |
| INCB 28050 |
| INCB-028050 |
| INCB-028050|||LY-3009104|||2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile |
| INCB028050 |
| ISP4442I3Y |
| J-503551 |
| KS-0000044L |
| LY 3009104 |
| LY-3009104 |
| LY3009104 |
| MFCD21608464 |
| MLS006011247 |
| NCGC00345839-01 |
| NCGC00345839-14 |
| Olumiant (TN) |
| PB27275 |
| QCR-197 |
| RL00725 |
| S-7686 |
| s2851 |
| SB10845 |
| SC-94301 |
| SCHEMBL871150 |
| SMR004703006 |
| SW220096-1 |
| UNII-ISP4442I3Y |
| XUZMWHLSFXCVMG-UHFFFAOYSA-N |
| Y0439 |
| ZINC73069247 |
US Patents and Regulatory Information for OLUMIANT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-002 | Oct 8, 2019 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OLUMIANT
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 2288610 | Start Trial |
| Luxembourg | C00027 | Start Trial |
| Croatia | P20161390 | Start Trial |
| Taiwan | 200942545 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for OLUMIANT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2288610 | CA 2017 00032 | Denmark | Start Trial | PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1 /16/1170 20170215 |
| 2288610 | 17C0005 | France | Start Trial | PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170215 |
| 2288610 | PA2017023 | Lithuania | Start Trial | PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
| 2288610 | PA2017023,C2288610 | Lithuania | Start Trial | PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
